Levopar

Levodopa and Benserazide, the active ingredient in Levopar, is a dopamine precursor / dopa decarboxylase inhibitor combination presented as an oral tablet formulation for oral use. It is employed to treat Parkinson's disease and related Parkinsonian syndromes in adult patients.

GNH USA supplies Levopar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Levopar is used in the management of movement disorders affecting the dopaminergic pathway.

- Parkinson's disease: improves motor symptoms such as tremor, rigidity and bradykinesia. - Parkinsonian syndrome: reduces rigidity and improves gait and posture. - Levodopa‑responsive Parkinsonism: provides symptomatic relief in patients who respond to dopaminergic therapy.

Levodopa and Benserazide may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: upset stomach often occurring at treatment initiation. - Vomiting: may accompany nausea, especially with rapid dose escalation. - Orthostatic hypotension: dizziness or light‑headedness upon standing. - Headache: mild to moderate intensity. - Insomnia: difficulty initiating or maintaining sleep. - Dyspepsia: indigestion or abdominal discomfort.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements that can be disabling. - Hallucinations or psychosis: visual or auditory disturbances, especially in older patients. - Severe hypotension: marked blood pressure drop leading to fainting. - Cardiac arrhythmias: irregular heart rhythms requiring medical attention. - Neuroleptic malignant‑like syndrome: rare but life‑threatening reaction with fever and muscle rigidity.

When prescribing Levopar, clinicians should observe several precautionary measures to ensure safe and effective therapy.

- Dose titration: start with a low dose and increase gradually to minimize adverse effects. - Blood pressure monitoring: watch for orthostatic hypotension, especially during initial therapy. - Renal and hepatic function: assess and adjust dosing in patients with impairment. - Abrupt discontinuation: avoid sudden stopping to prevent withdrawal and worsening of symptoms. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Levopar can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): may cause hypertensive crisis. - Dopamine antagonists (e.g., typical antipsychotics): reduce therapeutic effect. - High‑protein meals: compete for intestinal transport, decreasing levodopa absorption.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure‑lowering effect. - SSRIs and SNRIs: may increase risk of serotonin syndrome. - Iron or vitamin B6 supplements: can diminish levodopa absorption; separate dosing times.